CN102552541B - Medicinal composition for preventing or treating breast cancer - Google Patents
Medicinal composition for preventing or treating breast cancer Download PDFInfo
- Publication number
- CN102552541B CN102552541B CN2012100123801A CN201210012380A CN102552541B CN 102552541 B CN102552541 B CN 102552541B CN 2012100123801 A CN2012100123801 A CN 2012100123801A CN 201210012380 A CN201210012380 A CN 201210012380A CN 102552541 B CN102552541 B CN 102552541B
- Authority
- CN
- China
- Prior art keywords
- parts
- breast carcinoma
- medicinal composition
- treatment
- breast cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010006187 Breast cancer Diseases 0.000 title claims abstract description 43
- 208000026310 Breast neoplasm Diseases 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title abstract description 13
- 201000008275 breast carcinoma Diseases 0.000 claims description 31
- 239000003814 drug Substances 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 241000717739 Boswellia sacra Species 0.000 claims description 13
- 241000628997 Flos Species 0.000 claims description 13
- 241000237636 Pheretima Species 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 13
- 241000545442 Radix Species 0.000 claims description 4
- 239000000463 material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- 239000004863 Frankincense Substances 0.000 abstract description 10
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 229940126678 chinese medicines Drugs 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 235000003130 Arctium lappa Nutrition 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 241000361919 Metaphire sieboldi Species 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 20
- 239000000706 filtrate Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 12
- 239000009636 Huang Qi Substances 0.000 description 10
- 230000002265 prevention Effects 0.000 description 10
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000006837 decompression Effects 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 238000004064 recycling Methods 0.000 description 8
- 238000001291 vacuum drying Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000009261 endocrine therapy Methods 0.000 description 5
- 229940034984 endocrine therapy antineoplastic and immunomodulating agent Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 239000003390 Chinese drug Substances 0.000 description 4
- 238000006424 Flood reaction Methods 0.000 description 4
- 238000007598 dipping method Methods 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 208000030270 breast disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006223 Breast discharge Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000004059 Male Breast Neoplasms Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- -1 and therefore Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 208000010907 male breast carcinoma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035911 sexual health Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for preventing or treating breast cancer, and relates to the technical field of Chinese medicines. The medicinal composition is prepared from the following active ingredients in part by weight: 10 to 15 parts of Chinese angelica, 8 to 12 parts of great burdock achene, 8 to 12 parts of safflower, 15 to 18 parts of mongolian dandelion herb, 8 to 12 parts of astragalus, 10 to 15 parts of frankincense, 6 to 10 parts of liquoric root, 8 to 12 parts of medlar and 15 to 18 parts of earthworm. The medicinal composition has an obvious curative effect, islow in cost and does not have toxic or side effects.
Description
Technical field
The invention belongs to the Chinese medicine technical field, be specifically related to the pharmaceutical composition of a kind of prevention or treatment breast carcinoma, relate in particular to a kind of pharmaceutical composition of breast cancer relapse afterwards that prevents to perform the operation.
Background technology
Cancer is common frdquently encountered disease, and the people's life and healthy in serious harm, because the position difference of pathogenesis of cancer can have various cancer, as breast carcinoma, gastric cancer, breast carcinoma, osteocarcinoma, skin carcinoma, intestinal cancer, hepatocarcinoma etc.
Breast carcinoma is one of modal malignant tumor of women, and according to statistics, sickness rate accounts for the 7-10% of the various malignant tumor of whole body.Its morbidity is often relevant with heredity, and the women's sickness rate between 40-60 years old, before and after menopause is higher.Only the mammary gland patient of about 1-2% is the male.Usually occurring in the malignant tumor of breast glandular epithelium tissue, is one of a kind of women's of having a strong impact on physical and mental health even life-threatening modal malignant tumor, and male breast carcinoma is rare.Cardinal symptom shows as: mammary gland tumor, mammary gland pain, nipple discharge, nipple change, the skin breast cancer cell changes, the axillary gland enlargement.
Along with the renewal of concept of health and the foundation of new medical model, improving of patient with breast cancer's existence and quality of life becomes the major issue that must consider in the clinical treatment.The scheme of clinical treatment breast carcinoma mainly comprises operation, radiotherapy, chemotherapy, endocrine therapy and Chinese medicine etc. at present.Found nearly 100 for many years from radical mastectomy, operation is one of main method for the treatment of breast carcinoma always, and especially focus is limited to part or lymph node patient's prefered method.But, studies show that the patient with breast cancer still is faced with higher risk of recurrence after first operation, the peak of its recurrence concentrates on about about 2 years.The research report of relevant breast carcinoma of early stage test cooperative groups (EBCTCG) shows, postoperative chemotherapy and endocrine therapy can make the year case fatality rate of breast carcinoma descend about 20%, adjuvant chemotherapy makes the breast carcinoma mortality rate with respect to descending about 25%, auxiliary endocrine therapy can make the breast carcinoma mortality rate 30%-40% that descends relatively, but chemotherapy, radiotherapy, and endocrine therapy often produce gastrointestinal reaction, leucocytes reduction, side effect such as alopecia.How when increasing breast carcinoma radiotherapy chemotherapy curative effect, reduce its toxic and side effects as far as possible, improve the attention that quality of life has caused this area research worker gradually.Clinical practice shows, the operation back cooperates the Chinese medicine decoction treatment can reduce relapse and metastasis, improve patients ' life quality, strengthen the patient to the tolerance of tumor radiotherapy chemotherapy and improve the patient immune function, can reduce the side effect of chemotherapy, radiotherapy, endocrine therapy simultaneously.
The Chinese medicine of the treatment breast carcinoma that in sum, the research searching is evident in efficacy, toxicity is low remains current medical science urgent problem.
Summary of the invention
In view of the deficiencies in the prior art, the object of the present invention is to provide a kind of pharmaceutical composition for the treatment of breast carcinoma of evident in efficacy, with low cost, almost non-toxic side effect, a kind of pharmaceutical composition of the back breast cancer relapse that prevents to perform the operation especially is provided.
The object of the present invention is achieved like this: the pharmaceutical composition of a kind of prevention or treatment breast carcinoma, made by the active component of following weight portion: Radix Angelicae Sinensis 10-15 part, Fructus Arctii 8-12 part, Flos Carthami 8-12 part, Herba Taraxaci 15-18 part, Radix Astragali 8-12 part, Olibanum 10-15 part, Radix Glycyrrhizae 6-10 part, Fructus Lycii 8-12 part, Pheretima 15-18 part.
In preferred embodiment of the present invention, the pharmaceutical composition of described prevention or treatment breast carcinoma is made by the active component of following weight portion: 12 parts of Radix Angelicae Sinensis, 10 parts of Fructus Arctiis, 10 parts on Flos Carthami, 16 parts of Herba Taraxacis, 10 parts of the Radixs Astragali, 12 parts of Olibanums, 8 parts in Radix Glycyrrhizae, 10 parts of Fructus Lycii, 16 parts of Pheretimas.
In another preferred embodiment of the present invention, the pharmaceutical composition of described prevention or treatment breast carcinoma is made by the active component of following weight portion: 10 parts of Radix Angelicae Sinensis, 10 parts of Fructus Arctiis, 8 parts on Flos Carthami, 15 parts of Herba Taraxacis, 12 parts of the Radixs Astragali, 15 parts of Olibanums, 8 parts in Radix Glycyrrhizae, 12 parts of Fructus Lycii, 15 parts of Pheretimas.
In another preferred embodiment of the present invention, the pharmaceutical composition of described prevention or treatment breast carcinoma is made by the active component of following weight portion: 15 parts of Radix Angelicae Sinensis, 12 parts of Fructus Arctiis, 12 parts on Flos Carthami, 18 parts of Herba Taraxacis, 8 parts of the Radixs Astragali, 10 parts of Olibanums, 10 parts in Radix Glycyrrhizae, 8 parts of Fructus Lycii, 8 parts of Pheretimas.
The pharmaceutical composition of above-mentioned any one prevention or treatment breast carcinoma is granule.
According to the record of Chinese medicine historical data, above-mentioned nine flavor Chinese medicines have following pharmacologically active:
Radix Angelicae Sinensis: having enriches blood invigorates blood circulation, the effect of menstruction regulating and pain relieving, loosening bowel to relieve constipation, is used for blood deficiency and yellow complexion, dizzy cardiopalmus, menoxenia, amenorrhea dysmenorrhea, asthenia cold abdominalgia, dryness of the intestine constipation, rheumatic arthralgia, injury from falling down, ulcer sores.
Fructus Arctii: have the effect of dispelling wind and heat pathogens, lung qi dispersing rash, sore-throat relieving eliminating stagnation, removing toxic substances and promoting subsidence of swelling, cure mainly that cough due to pathogenic wind-heat, laryngopharynx swelling and pain, macule are saturating, rubella pruritus, sore swollen toxin.
Flos Carthami: the effect with the latus rectum of invigorating blood circulation, eliminating stasis to stop pain.Be used for that amenorrhea, dysmenorrhea, lochia are not all right, lump in the abdomen mass in the abdomen, traumatic injury.
Herba Taraxaci: have heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, the effect of inducing diuresis for treating stranguria syndrome.Be used for furuncle swelling toxin, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, lung abscess, acute appendicitis, jaundice due to damp-heat, the puckery pain of pyretic stranguria.
The Radix Astragali: have the effect that benefiting QI for strengthening the superficies, arresting sweating take off, hold in the palm skin ulcer granulation promoting, inducing diuresis to remove edema admittedly.It is weak to be used for the treatment of the deficiency of vital energy, sinking of QI of middle-JIAO, and the chronic diarrhea proctoptosis, the metrorrhagia of having blood in stool, the exterior deficiency spontaneous perspiration, carbuncle is difficult bursts, and burst for a long time and do not hold back, blood deficiency and yellow complexion, interior-heat is quenched one's thirst, chronic nephritis, albuminuria, diabetes etc.The invigorating middle warmer of Radix Astragali Preparata QI invigorating is given birth to consolidating superficial resistance holder skin ulcer.
Olibanum: have regulating qi and activating blood, analgesic therapy chases after malicious effect.Be used for regulating qi and activating blood, analgesic therapy chases after poison.Control coagulation of QI-blood, trusted subordinate's pain, carbuncle pyogenic infections from tumour or sore, traumatic injury, dysmenorrhea, postnatal blood stasis twinge.
Radix Glycyrrhizae: have invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, the effect of coordinating the actions of various ingredients in a prescription.Be used for weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, the anxious pain of extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Fructus Lycii: have nourishing the liver and kidney, the effect of replenishing vital essence to improve eyesight.Be used for the asthenia damage of essence, soreness of waist and knee joint, vertigo and tinnitus, interior-heat is quenched one's thirst, blood deficiency and yellow complexion, blurred vision is not clear.
Pheretima: the effect with heat clearing away, spasmolytic, Zhichuan, diuresis.Cure mainly that hyperpyrexia is manic, convulsion with spasms, headache conjunctival congestion, the diseases such as expectorant heat, apoplexy, hemiplegia of panting.
The preparation method that above-mentioned each Chinese medicinal components is prepared into compound preparation of the present invention is:
(1) Radix Angelicae Sinensis, Fructus Arctii, the Radix Astragali with recipe quantity adds 80% alcohol dipping three times, floods 48 hours for the first time, and second and third time flooded respectively 24 hours, filters, and decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(2) Flos Carthami, Herba Taraxaci, Olibanum, Radix Glycyrrhizae, Fructus Lycii, the Pheretima that will remain recipe quantity adds 10 times of water gagings and decocts three times, and 1 hour for the first time, second and third time 0.5 hour, filter, merging filtrate, it is 1.05-1.10(50-60 ℃ that filtrate is condensed into relative density) clear paste, add 2.8 times of amount ethanol, stir, be heated to 60 ℃, left standstill 24 hours, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(3) step (1) get dry extract is got dry extract with step (2) mix, be ground into fine powder, add pharmaceutically acceptable granule.
Adopt mutual compatibility of above-mentioned raw material of Chinese medicine and preparation method thereof, full side has promoting the circulation of QI to relieve pain, active lactogenesis, sets upright, eliminating evil, improve the effect that endocrine improves immunologic function except the stasis of blood, toxin expelling, adjusting hormonal balance, thereby reach the purpose of efficient treatment breast carcinoma of early stage, be used for the treatment of breast carcinoma clinically.
Chinese medicine composition of the present invention in the mice in vitro tests usage and dosage: oral, irritate stomach and give the present invention the dried cream powder aqueous solution of preparation, dosage is 65g crude drug/kg, 1 time/day, administration is 60 altogether.
The present invention has following useful effect and obvious improvement: (1) result of the test shows (referring to table 1), compare with model control group, each treatment group to the inhibitory action of the growth of MA-891 mouse breast cancer model all have utmost point significant difference (
P＜0.01), this illustrates that Chinese medicine composition of the present invention has extremely significant curative effect aspect the treatment breast carcinoma.In addition, Chinese drug-treated group of the present invention is compared aspect the tumour inhibiting rate with chemotherapy 5-FU group does not have significant difference, 2 of the dead mouses of administration end back chemotherapy group, this curative effect that Chinese medicine composition of the present invention is described is suitable with chemotherapeutics, and when obtaining remarkable drug effect, have the low advantage of toxic and side effects, obtained unforeseeable technique effect.(2) the present invention has the advantage that flavour of a drug are few, dosage is little, curative effect is high, generally easily adopt in the medicine source, does not have famous and precious Chinese medicine, and therefore, pharmaceutical composition of the present invention is as the anti-breast cancer medicine, and its cost is low, patient's interdependence height.
The specific embodiment
Below be specific embodiments of the invention, technical scheme of the present invention is done further the description, but protection scope of the present invention is not limited to these embodiment.Every do not deviate from the change of the present invention design or be equal to substitute include within protection scope of the present invention.
The preparation of the Chinese medicine granules of embodiment 1 prevention or treatment breast carcinoma
The crude drug prescription:
| Radix Angelicae Sinensis 120g | Fructus Arctii 100g | Flos Carthami 100g |
| Herba Taraxaci 160g | Radix Astragali 100g | Olibanum 120g |
| Radix Glycyrrhizae 80g | Fructus Lycii 100g | Pheretima 160g. |
The preparation method of granule:
(1) Radix Angelicae Sinensis, Fructus Arctii, the Radix Astragali with recipe quantity adds 80% alcohol dipping three times, floods 48 hours for the first time, and second and third time flooded respectively 24 hours, filters, and decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(2) Flos Carthami, Herba Taraxaci, Olibanum, Radix Glycyrrhizae, Fructus Lycii, the Pheretima that will remain recipe quantity adds 10 times of water gagings and decocts three times, and 1 hour for the first time, second and third time 0.5 hour, filter, merging filtrate, it is 1.05-1.10(50-60 ℃ that filtrate is condensed into relative density) clear paste, add 2.8 times of amount ethanol, stir, be heated to 60 ℃, left standstill 24 hours, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(3) step (1) get dry extract is got dry extract with step (2) mix, be ground into fine powder, add cane sugar powder, make granule.
The preparation of the Chinese medicine granules of embodiment 2 preventions or treatment breast carcinoma
The crude drug prescription:
| Radix Angelicae Sinensis 100g | Fructus Arctii 100g | Flos Carthami 80g |
| Herba Taraxaci 150g | Radix Astragali 120g | Olibanum 150g |
| Radix Glycyrrhizae 80g | Fructus Lycii 120g | Pheretima 150g. |
The preparation method of granule:
(1) Radix Angelicae Sinensis, Fructus Arctii, the Radix Astragali with recipe quantity adds 80% alcohol dipping three times, floods 48 hours for the first time, and second and third time flooded respectively 24 hours, filters, and decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(2) Flos Carthami, Herba Taraxaci, Olibanum, Radix Glycyrrhizae, Fructus Lycii, the Pheretima that will remain recipe quantity adds 10 times of water gagings and decocts three times, and 1 hour for the first time, second and third time 0.5 hour, filter, merging filtrate, it is 1.05-1.10(50-60 ℃ that filtrate is condensed into relative density) clear paste, add 2.8 times of amount ethanol, stir, be heated to 60 ℃, left standstill 24 hours, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(3) step (1) get dry extract is got dry extract with step (2) mix, be ground into fine powder, add cane sugar powder, make granule.
The preparation of the Chinese medicine granules of embodiment 3 preventions or treatment breast carcinoma
The crude drug prescription:
| Radix Angelicae Sinensis 150g | Fructus Arctii 120g | Flos Carthami 120g |
| Herba Taraxaci 180g | Radix Astragali 80g | Olibanum 100g |
| Radix Glycyrrhizae 100g | Fructus Lycii 80g | Pheretima 180g. |
The preparation method of granule:
(1) Radix Angelicae Sinensis, Fructus Arctii, the Radix Astragali with recipe quantity adds 80% alcohol dipping three times, floods 48 hours for the first time, and second and third time flooded respectively 24 hours, filters, and decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(2) Flos Carthami, Herba Taraxaci, Olibanum, Radix Glycyrrhizae, Fructus Lycii, the Pheretima that will remain recipe quantity adds 10 times of water gagings and decocts three times, and 1 hour for the first time, second and third time 0.5 hour, filter, merging filtrate, it is 1.05-1.10(50-60 ℃ that filtrate is condensed into relative density) clear paste, add 2.8 times of amount ethanol, stir, be heated to 60 ℃, left standstill 24 hours, filter, decompression filtrate recycling ethanol is condensed into the thick paste shape, and vacuum drying below 85 ℃ becomes dried cream;
(3) step (1) get dry extract is got dry extract with step (2) mix, be ground into fine powder, add cane sugar powder, make granule.
Embodiment 4 pharmaceutical compositions of the present invention are to the inhibitory action of transplantability breast carcinoma
(1) preparation of transplantability breast carcinoma mouse model
36 of the female Sexual health TA2 of SPF level mices, 6 ages in week, body constitution amount l6g-18 g.Get the exponential phase MA-891 mouse mastopathy cell of In vitro culture, adjusting the MA-891 cell concentration with aseptic PBS is 1 * 10
7/ mL.Under aseptic condition, it is subcutaneous that the MA-891 mouse mastopathy cell is inoculated in the right armpit of TA2 mice, and inoculum concentration is that only (cell number is 2 * 10 to 0.2ml/
6/ only).Whole seeded process must be carried out with the sterile working in aseptic cover, finishes inoculation in the 1h.Treat that subcutaneous transplantation tumor volume reaches 60 mm
3During the left and right sides (about lOd), model manufacturing success.
(2) grouping and administration
Be divided into following 3 groups by tumor volume and mice with tumor body weight homeostatic principle, 12 every group:
Model control group: the normal saline of filling stomach equivalent 1 time/day, administration is 60 altogether;
Chinese drug-treated group: irritate stomach and give embodiment the granule aqueous solution of 1 preparation, dosage is 65g crude drug/kg, and 1 time/day, administration is 60 altogether;
5-FU group: lumbar injection 10mg/kg oxaliplatin, the next day administration 1 time, amount to 10 times.
Mice is put to death in dislocation behind last administration 48 h, and excision transplanted tumor takes by weighing tumor and weighs.Heavy suppression ratio (%) IR of tumor=(1-experimental group tumor weight-average value/model control group tumor weight-average value) * 100%.Relatively the embody medicine heavy by tumor suppresses the influence that tumor is grown to mouse breast cancer MA-891 cell.(x ± s) expression adopts SPSS15.0 software to carry out variance analysis to data with mean ± standard deviation.
(3) result and analysis
Result of the test shows (referring to table 1): compare with model control group, each treatment group to the inhibitory action of the growth of MA-891 mouse breast cancer model all have utmost point significant difference (
P＜0.01), this illustrates that Chinese medicine composition of the present invention has extremely significant curative effect aspect the treatment breast carcinoma.In addition, Chinese drug-treated group of the present invention is compared aspect the tumour inhibiting rate with chemotherapy 5-FU group does not have significant difference, 2 of the dead mouses of administration end back chemotherapy group, this curative effect that Chinese medicine composition of the present invention is described is suitable with chemotherapeutics, and when obtaining remarkable drug effect, have the low advantage of toxic and side effects, obtained unforeseeable technique effect.
Table 1 pharmaceutical composition of the present invention is to the inhibitory action of transplantability breast carcinoma
| Group | Sample size (beginning/finish) | Tumor weight/g | Average tumour inhibiting rate/% |
| Model control group | 12/12 | 1.41±0.22 | ? |
| The 5-FU group | 12/10 | 0.57±0.25 ** | 59.6 |
| Chinese drug-treated group | 12/12 | 0.59±0.19 ** | 58.2 |
Compare * * with model control group
P＜0.01.
Owing to described the present invention by above embodiment, any to be equal to replacement all be apparent for the present invention and be included among the present invention.
Claims (2)
1. a pharmaceutical composition for the treatment of breast carcinoma is characterized in that being prepared from by following parts by weight of Chinese traditional medicine material: 12 parts of Radix Angelicae Sinensis, 10 parts of Fructus Arctiis, 10 parts on Flos Carthami, 16 parts of Herba Taraxacis, 10 parts of the Radixs Astragali, 12 parts of Olibanums, 8 parts in Radix Glycyrrhizae, 10 parts of Fructus Lycii, 16 parts of Pheretimas.
2. a kind of pharmaceutical composition for the treatment of breast carcinoma as claimed in claim 1, it is characterized in that: described pharmaceutical composition is granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100123801A CN102552541B (en) | 2012-01-16 | 2012-01-16 | Medicinal composition for preventing or treating breast cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012100123801A CN102552541B (en) | 2012-01-16 | 2012-01-16 | Medicinal composition for preventing or treating breast cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552541A CN102552541A (en) | 2012-07-11 |
| CN102552541B true CN102552541B (en) | 2013-09-25 |
Family
ID=46399996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012100123801A Active CN102552541B (en) | 2012-01-16 | 2012-01-16 | Medicinal composition for preventing or treating breast cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552541B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106511846A (en) * | 2017-01-20 | 2017-03-22 | 叶红燕 | Anticancer medicinal liquor and making method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682787A (en) * | 2004-04-12 | 2005-10-19 | 张运通 | Ruankang good for breast |
| CN102133378A (en) * | 2011-03-23 | 2011-07-27 | 何玉伟 | Medicament for treating breast cancer |
-
2012
- 2012-01-16 CN CN2012100123801A patent/CN102552541B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1682787A (en) * | 2004-04-12 | 2005-10-19 | 张运通 | Ruankang good for breast |
| CN102133378A (en) * | 2011-03-23 | 2011-07-27 | 何玉伟 | Medicament for treating breast cancer |
Non-Patent Citations (4)
| Title |
|---|
| 乳腺病中医治法与用药分析;徐列波;《中国药业》;20080120;第17卷(第02期);58-59，第58页右栏第2、3段，第59页左栏第1段 * |
| 徐列波.乳腺病中医治法与用药分析.《中国药业》.2008,第17卷(第02期),58-59，第58页右栏第2、3段，第59页左栏第1段. |
| 王桂绵主任医师治疗乳腺癌的经验;闫洪飞等;《中国中西医结合外科杂志》;20020830;第08卷(第04期);305-306 * |
| 闫洪飞等.王桂绵主任医师治疗乳腺癌的经验.《中国中西医结合外科杂志》.2002,第08卷(第04期),305-306. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552541A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101342271B (en) | Traditional Chinese medicine for treating qi-blood deficiency caused by tumour chemotherapy and preparation method thereof | |
| CN111375010A (en) | A Chinese medicinal composition with effects of strengthening body resistance, consolidating constitution, nourishing liver, invigorating kidney, and enhancing immunity | |
| CN104491740A (en) | Traditional Chinese medicine composition for treating liver cancer and preparation method of traditional Chinese medicine composition | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN103054990B (en) | Traditional Chinese medicine for treating functional abdominal pain in children and preparation method thereof | |
| CN102772523B (en) | Bitter glossy ganoderma composition for oncotherapy and preparation method of bitter glossy ganoderma composition | |
| CN113730535A (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application of traditional Chinese medicine preparation of traditional Chinese medicine composition | |
| CN105213974A (en) | One treats lymphadenomatous Chinese medicine composition and application thereof | |
| CN104383317A (en) | Chinese traditional medicine composition for treating liver cancer | |
| CN101564464B (en) | Chinese medicament for adjusting organism immunity of tumor patients | |
| CN102552541B (en) | Medicinal composition for preventing or treating breast cancer | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN106902307A (en) | A kind of Chinese medicine composition and usage for treating malignant tumor of lung | |
| CN102846739A (en) | Navel-applied plaster for treating hepatitis and preparation method thereof | |
| CN105816813A (en) | Medicine composition for treating breast cancer and preparing method and application of medicine composition | |
| CN103536674B (en) | Medicament composition capable of preventing melanin tumor | |
| CN104383349A (en) | Drug for postoperative recovery of bladder cancer and preparation method of drug for postoperative recovery of bladder cancer | |
| CN104888128A (en) | Traditional Chinese medicine composition for treatment of cancers | |
| CN103405721A (en) | Pharmaceutical composition for inhibiting tumor metastasis and application thereof | |
| CN114869987B (en) | Traditional Chinese medicine composition for preventing liver cancer | |
| CN102423369B (en) | Chinese medicinal composition for preventing or treating ovarian cancer | |
| CN102688453A (en) | Traditional Chinese medicine composite for treating breast cancer | |
| CN1256976C (en) | Anti-cancer Chinese medicinal composition and its preparing method | |
| CN105311578A (en) | Traditional Chinese medicine composition for treating intracranial tumors | |
| CN104758749A (en) | Traditional Chinese medicine composition for treating liver cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LI WEILI Free format text: FORMER OWNER: XU CONGYU Effective date: 20130325 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Cuiwei Inventor before: Zhang Lihua |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG LIHUA TO: WANG CUIWEI Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 266200 QINGDAO, SHANDONG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20130325 Address after: Jimo City, Shandong province 266200 Jhengtong street Qingdao City No. 20 Applicant after: Li Weili Address before: 276017 A302 building, Linyi hi tech Industrial Development Zone, Shandong, China Applicant before: Xu Congyu |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG SANJIANG CONSTRUCTION MACHINERY CO., LTD. Free format text: FORMER OWNER: LI WEILI Effective date: 20140728 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 266200 QINGDAO, SHANDONG PROVINCE TO: 226200 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140728 Address after: 226200 Nanhai Road, Binhai Industrial Park, Nantong, Jiangsu, Qidong Patentee after: Qidong Sanjiang Construction Machinery Co., Ltd. Address before: Jimo City, Shandong province 266200 Jhengtong street Qingdao City No. 20 Patentee before: Li Weili |